- Home
- SPAI vs RLYB Comparison
SPAI vs RLYB Comparison
Compare SPAI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | RLYB |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 86.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPAI | RLYB |
|---|---|---|
| Price | $4.55 | $16.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 73.3K | 38.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $3.23 | $0.40 |
| 52 Week High | $9.16 | $17.57 |
Technical Indicators
Market Signals| Indicator | SPAI | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 54.70 |
| Support Level | $3.57 | $15.60 |
| Resistance Level | $4.74 | $16.50 |
| Average True Range (ATR) | 0.29 | 0.46 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 74.31 | 27.42 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.